| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/17/2003 | WO2003057249A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | WO2003057239A1 Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis |
| 07/17/2003 | WO2003057233A1 Composition for preventing or treating mastitis of dairy cattle |
| 07/17/2003 | WO2003057227A1 Use of polysaccharide derivatives as anti-infective substances |
| 07/17/2003 | WO2003057226A1 Use of phospholipids in peritoneal dialysis |
| 07/17/2003 | WO2003057225A2 Phosphate transport inhibitors |
| 07/17/2003 | WO2003057224A1 Apoptosis inductor |
| 07/17/2003 | WO2003057223A1 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
| 07/17/2003 | WO2003057222A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/17/2003 | WO2003057220A1 Cyclic urea derivatives with 5-ht2c receptor activity |
| 07/17/2003 | WO2003057219A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| 07/17/2003 | WO2003057218A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 07/17/2003 | WO2003057217A1 Combinations comprising epothilones and anti-metabolites |
| 07/17/2003 | WO2003057216A1 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 07/17/2003 | WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases. |
| 07/17/2003 | WO2003057210A1 Compositions and methods for increasing cell proliferation comprising a flavonoid |
| 07/17/2003 | WO2003057209A1 Method for the preparation of matairesinol |
| 07/17/2003 | WO2003057208A1 Taxane based compositions and methods of use |
| 07/17/2003 | WO2003057207A1 Methods for treating hearing loss |
| 07/17/2003 | WO2003057206A1 Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof |
| 07/17/2003 | WO2003057205A2 Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs |
| 07/17/2003 | WO2003057203A2 Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours |
| 07/17/2003 | WO2003057202A1 Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
| 07/17/2003 | WO2003057201A2 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | WO2003057200A2 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 07/17/2003 | WO2003057198A1 Pharmaceutical formulations with modified release |
| 07/17/2003 | WO2003057196A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | WO2003057195A1 Pravastatin pharmaceutical formulations and methods of their use |
| 07/17/2003 | WO2003057194A1 Sterile filtered nanoparticule formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
| 07/17/2003 | WO2003057188A1 Delivery of caffeine through an inhalation route |
| 07/17/2003 | WO2003057187A1 Combinations of viscoelastics for use during surgery |
| 07/17/2003 | WO2003057184A2 Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners |
| 07/17/2003 | WO2003057177A2 Counteracting bioprosthetic calcification |
| 07/17/2003 | WO2003057176A2 Porphyrins with virucidal activity |
| 07/17/2003 | WO2003057173A2 Broad spectrum inhibitors |
| 07/17/2003 | WO2003057172A2 Topical application of alpha-dfmo and anti-inflammatory drug for treatment of actinic keratoses |
| 07/17/2003 | WO2003057169A2 4-dedimethylamino tetracycline compounds |
| 07/17/2003 | WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | WO2003057165A2 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
| 07/17/2003 | WO2003057163A2 Methods for preparing immunoconjugates |
| 07/17/2003 | WO2003057162A2 Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases |
| 07/17/2003 | WO2003057159A2 Psoriasin expression by breast epithelial cells |
| 07/17/2003 | WO2003057154A2 Naaladase inhibitors for treating huntington's disease |
| 07/17/2003 | WO2003057153A2 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 07/17/2003 | WO2003057151A2 A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| 07/17/2003 | WO2003057150A2 A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
| 07/17/2003 | WO2003057147A2 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/17/2003 | WO2003057145A2 SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES |
| 07/17/2003 | WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057141A2 Methods for improving the aesthetic appearance of skin |
| 07/17/2003 | WO2003057140A2 Composition and methods for treatment of neurological disorders |
| 07/17/2003 | WO2003057136A2 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | WO2003057135A2 Aqueous compositions containing metronidazole |
| 07/17/2003 | WO2003057134A2 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | WO2003057072A2 Hemostatic compositions and methods for controlling bleeding |
| 07/17/2003 | WO2003057012A2 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| 07/17/2003 | WO2003057007A2 System for monitoring bacterial tumor treatment |
| 07/17/2003 | WO2003056931A1 Chewing gum composition for eliminating nicotine |
| 07/17/2003 | WO2003056913A1 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/17/2003 | WO2003056899A2 Nitric oxide donors for treatment of disease and injury |
| 07/17/2003 | WO2003049672A3 Methods and compositions for treating flavivirus-mediated disease |
| 07/17/2003 | WO2003043974A3 New pharmaceutical compounds |
| 07/17/2003 | WO2003039488A3 A method for treating inflammatory bowel disease |
| 07/17/2003 | WO2003034994A3 Gentle-acting skin-disinfectants and hydroalcoholic gel formulations |
| 07/17/2003 | WO2003032962A3 Dual action antibiotics |
| 07/17/2003 | WO2003030827A3 Compositions for and methods of treating and preventing sirs/sepsis |
| 07/17/2003 | WO2003026641A8 Modulation of stat activity |
| 07/17/2003 | WO2003022809A3 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain |
| 07/17/2003 | WO2003022252A3 Combinatorial type (several vehicles within a housing) controlled release drug delivery device |
| 07/17/2003 | WO2003020371A3 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer |
| 07/17/2003 | WO2003008573A3 Silencing of gene expression by sirna |
| 07/17/2003 | WO2003008410A3 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 07/17/2003 | WO2003003987A3 Solid phase synthesis of arylretinamides |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002102340A3 Use of carnitine and/or one or more acyl-carnitines for producing cosmetic or dermatological preparations |
| 07/17/2003 | WO2002099044A3 B3galts as modifiers of the p53 pathway and methods of use |
| 07/17/2003 | WO2002094259B1 Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
| 07/17/2003 | WO2002083928A3 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 07/17/2003 | WO2002076434A3 Nicotinic receptor agonists for the treatment of inflammatory diseases |
| 07/17/2003 | WO2002067938A3 Treating or reducing the risk of cardiovascular disease |
| 07/17/2003 | WO2002058323A3 Method for identifying modulators of bace |
| 07/17/2003 | WO2002055693A3 Method for inhibiting the expression of a target gene |
| 07/17/2003 | WO2002055496A8 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| 07/17/2003 | WO2002055495A8 Aryl piperidine derivatives as inducers of ldl-receptor expression |
| 07/17/2003 | WO2002055020A3 Topical testosterone formulations and associated methods |
| 07/17/2003 | WO2002046190A3 Sulfonamido ether substituted imidazoquinolines |
| 07/17/2003 | WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses |
| 07/17/2003 | WO2002017858A9 Role of fosb in bone formation |
| 07/17/2003 | WO2002011713A3 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 07/17/2003 | WO2002009723A3 Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
| 07/17/2003 | WO2002009677A3 Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs |
| 07/17/2003 | WO2002003973A3 Compositions comprising isosorbide dinitrate and methods for treatment of anal fissure |
| 07/17/2003 | WO2001094369A3 Heterocycle derivatives and methods of use for treating anthrax infection |
| 07/17/2003 | WO1999044581A3 Pharmaceutical composition of topiramate |
| 07/17/2003 | US20030135874 Treating pain and urogenital disorders; G-protein coupled receptors; analgesics |
| 07/17/2003 | US20030135238 In situ bonds |
| 07/17/2003 | US20030135196 Irrigating via the flow pathway the area of the hemorrhage with a synthetic cerebrospinal fluid to reduce an indication of the presence of blood in effluent from the outflow catheter. |
| 07/17/2003 | US20030135195 Mixture of colloidal aliphatic polyurethane, an aqueous dilution of PVP and specific dendrimers to enhance the physical integrity of the coating, to improve adhesion and to covalently bind an anticoagulant or antibiotic drug |
| 07/17/2003 | US20030135063 Especially Type II diabetes; stimulating the kinase activity of the insulin receptor; activating the insulin receptor |
| 07/17/2003 | US20030135060 Bearing O-linked and N-linked substituents in the 10-position; antioxidant and antiproliferative activities. |